$13.420
-0.030 (-0.22%)At close
SLN News
SLN Events
Significant Increases in Borrow Rates for Liquid Options
Latest data shows the largest indicative borrow rate increases among liquid option names include: iShares Global Clean Energy (ICLN) 20.40% +7.74, Live Microsystems (LVWR) 391.27% +5.91, Faraday Future Intelligent Electric Inc (FFAI) 315.21% +1.06, SILENCE THERAPEUTICS PLC SPONSORED ADR (SLN) 1.05% +0.63, Ericsson (ERIC) 3.49% +0.62, Tradr 2X Short SNDK Daily ETF (SNDQ) 39.77% +0.44, Western Union (WU) 1.34% +0.40, Defiance Daily Target 2X Long RKLB ETF (RKLX) 13.91% +0.35, Tradr 2X Long CRWV Daily ETF (CWVX) 7.01% +0.34, and NovaDel Pharma (NVDL) 12.49% +0.30.
Jefferies, Morgan Stanley, and Others Jointly Manage Proposed Offering
Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book-running managers for the proposed offering.
Silence Therapeutics Reports Positive Phase 2 Results for Divesiran
Silence Therapeutics announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera. The 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran administered subcutaneously every six weeks or every twelve weeks met its primary endpoint and secondary endpoints. Key findings from the study include: The primary endpoint was met, with a significantly higher proportion of clinical responders among divesiran-treated patients with PV compared to those who received placebo. The primary endpoint was the proportion of patients achieving a response, which was defined as the absence of phlebotomy and maintenance of hematocrit below 45% during weeks 18-36. Both divesiran dose groups showed substantial primary endpoint efficacy with response rates of 93.8% and 81.3% for Q6W and Q12W, respectively. The key secondary endpoint of phlebotomy rate during weeks 0-36 was also met with the mean number of phlebotomies per patient in the divesiran groups significantly reduced compared to placebo.
SLN365 and SLN098 Preclinical Data Updates
Cash and cash equivalents were $72.1 million as of June 30, 2026. Pre-clinical pipeline updates: Generated additional preclinical data demonstrating the effect of SLN365 on lipids was reproduced and not altered by co-treatment with statin or ezetimibe. The program is well positioned for a potential IND filing in 2027. Generated additional preclinical data for SLN098 in a diet induced obesity mouse model demonstrating reduced visceral fat and preservation of lean body mass. The program is well positioned for a potential IND filing in 2027.
Silence Therapeutics Files $300M Ordinary Shares Offering
Silence Therapeutics files $300M ordinary shares offering
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.